{"id":"W3215111763","doi":"10.1016/j.ejca.2021.09.024","title":"KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; University of Toronto; Jewish General Hospital; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Trametinib; Pembrolizumab; Dosing; Medicine; Adverse effect; Internal medicine; Melanoma; Oncology; Immunotherapy; MAPK/ERK pathway; Cancer; Cancer research; Biology; Kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003222239,0.0003446164,0.0004603518,0.0001943443,0.0002733534,0.0005016063,0.000305904,0.0005779546,0.01152747],"category_scores_gemma":[0.0004097506,0.0001321574,0.0004096166,0.0002554983,0.0001213772,0.0004582102,0.0002010511,0.0009296002,0.001796575],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004580873,"about_ca_system_score_gemma":0.0004462167,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005217494,"about_ca_topic_score_gemma":0.002164612,"domain_scores_codex":[0.9998721,0.00003156828,0.00001219565,0.0000259335,0.00001657975,0.00004161009],"domain_scores_gemma":[0.9998834,0.00002063683,0.0000208253,0.000005220096,0.00001089171,0.00005904754],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2089307,0.002776821,0.05847166,0.002081558,0.001815959,0.003331888,0.000169644,0.001552951,0.04346767,0.00146081,0.109902,0.5660384],"study_design_scores_gemma":[0.09279478,0.05867525,0.4972465,0.00126276,0.003977395,0.01370963,0.0003837504,0.004686979,0.01992803,0.002355252,0.3047885,0.0001911714],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.897873,0.0291368,0.0006042327,0.009548478,0.001708827,0.0005601597,0.004035818,0.0002396511,0.05629304],"genre_scores_gemma":[0.9753321,0.004882889,0.0008575431,0.002418381,0.0006427688,0.0002318001,0.003173094,0.00002603313,0.01243538],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01152747,"threshold_uncertainty_score":0.03856325,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00713408438545517,"score_gpt":0.2450016289339794,"score_spread":0.2378675445485242,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}